BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 8324150)

  • 21. In vitro activity of ceftriaxone combined with tazobactam against anaerobic bacteria.
    Wüst J; Hardegger U
    Eur J Clin Microbiol Infect Dis; 1994 Feb; 13(2):177-81. PubMed ID: 8013494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria.
    Appelbaum PC
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():29-38. PubMed ID: 8383654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States.
    Aldridge KE; Gelfand M; Reller LB; Ayers LW; Pierson CL; Schoenknecht F; Tilton RC; Wilkins J; Henderberg A; Schiro DD
    Diagn Microbiol Infect Dis; 1994 Apr; 18(4):235-41. PubMed ID: 7924220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of resistance to anaerobic organisms in Australia.
    Munro R
    Diagn Microbiol Infect Dis; 1989; 12(4 Suppl):159S-163S. PubMed ID: 2591175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Detection of beta-lactamases in the Bacteroides fragilis group].
    Martin C; Dubreuil L; Sedallian A; Romond C
    Pathol Biol (Paris); 1990 May; 38(5):470-3. PubMed ID: 2367153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987.
    Cornick NA; Cuchural GJ; Snydman DR; Jacobus NV; Iannini P; Hill G; Cleary T; O'Keefe JP; Pierson C; Finegold SM
    J Antimicrob Chemother; 1990 Jun; 25(6):1011-9. PubMed ID: 2370237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of cefoperazone/sulbactam and other antimicrobials against anaerobic bacteria.
    D'Amato RF; Hochstein L; Frankel H
    Diagn Microbiol Infect Dis; 1990; 13(1):51-5. PubMed ID: 2331850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Susceptibility of anaerobic bacteria to Sch 34343 and other beta-lactam antibiotics.
    Jacobus NV; Tally FP; Gorbach SL
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():189-91. PubMed ID: 4030547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns.
    Aldridge KE; Ashcraft D; O'Brien M; Sanders CV
    Antimicrob Agents Chemother; 2003 Jan; 47(1):148-53. PubMed ID: 12499183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of beta-lactamase inhibitors on the activities of various beta-lactam agents against anaerobic bacteria.
    Wexler HM; Molitoris E; Finegold SM
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1219-24. PubMed ID: 1929265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the inoculum effect of cefoxitin and other cephalosporins and of beta-lactamase inhibitors and their penicillin-derived components on the Bacteroides fragilis group.
    Goldstein EJ; Citron DM; Cherubin CE
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1868-74. PubMed ID: 1952860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survey of the susceptibility patterns of Bacteroides fragilis group strains in France from 1977 to 1992.
    Dubreuil L; Breuil J; Dublanchet A; Sedallian A
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1094-9. PubMed ID: 1295764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [ESBL-positive strains of the Bacteroides fragilis group isolated from patients at the regional hospital center in Płock (Poland)].
    Rokosz A; Pawłowska J; Sawicka-Grzelak A; Luczak M
    Med Dosw Mikrobiol; 2004; 56(3):245-53. PubMed ID: 15773501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial susceptibility of anaerobic bacteria in Australia.
    Chen SC; Gottlieb T; Palmer JM; Morris G; Gilbert GL
    J Antimicrob Chemother; 1992 Dec; 30(6):811-20. PubMed ID: 1289355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An in-vitro and in-vivo comparison of the activity of beta-lactamase inhibitor combinations with imipenem and cephalosporins against Escherichia coli producing TEM-1 or TEM-2 beta-lactamase.
    Cherubin CE; Eng RH; Smith SM; Tan EN
    J Antimicrob Chemother; 1991 Jul; 28(1):61-70. PubMed ID: 1769944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996.
    Snydman DR; Jacobus NV; McDermott LA; Supran S; Cuchural GJ; Finegold S; Harrell L; Hecht DW; Iannini P; Jenkins S; Pierson C; Rihs J; Gorbach SL
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2417-22. PubMed ID: 10508018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to beta-lactam antibiotics in anaerobic bacteria.
    Nord CE; Hedberg M
    Rev Infect Dis; 1990; 12 Suppl 2():S231-4. PubMed ID: 2406875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparative in vitro activity of ampicillin, cefoperazone and their combinations with sulbactam, as well as that of other antibiotics against anaerobic organisms].
    Rezvan SP; Sidorenko SV; Budanov SV
    Antibiot Khimioter; 1995 Apr; 40(4):25-9. PubMed ID: 7654095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implications of beta-lactamase-inhibitor combinations.
    Fuchs PC; Barry AL
    J Reprod Med; 1990 Mar; 35(3 Suppl):317-21. PubMed ID: 2319514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging resistance of anaerobic bacteria to antimicrobial agents in South Korea.
    Lee K; Chong Y; Jeong SH; Xu XS; Kwon OH
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S73-7. PubMed ID: 8953110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.